Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival Elizabeth A. David, MD, Robert J. Canter,

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Elizabeth A. David, MD, David T

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Benny Weksler, MD, Jennifer L. Sullivan, MD

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Chun Chieh Lin, PhD, MBA, Matthew P

Joshua E. Rosen, BASc, Hari B

Ravi Rajaram, MD, MSc, Jennifer L

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A

Matthew D. Taylor, MD, Alykhan S. Nagji, MD, Castigliano M

Oncologic Outcomes After Surgical Resection of Subcentimeter Non-Small Cell Lung Cancer Matthew J. Schuchert, MD, Arman Kilic, BS, Arjun Pennathur, MD,

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Increased Time From Neoadjuvant Chemoradiation to Surgery Is Associated With Higher Pathologic Complete Response Rates in Esophageal Cancer Talha Shaikh,

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients Elizabeth A. David, MD, Stina W. Andersen, PhD,

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Castigliano M. Bhamidipati, DO, MS, George J

Second Primary Lung Cancers: Smokers Versus Nonsmokers After Resection of Stage I Lung Adenocarcinoma R. Taylor Ripley, MD, Robert R. McMillan, MD, MPH,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li,

Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer Justin A. Drake, MD, David C. Portnoy, MD, Kurt.

Andrea S. Wolf, MD, MPH, Scott J

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Chris Dickhoff, MD, Max Dahele, MD, PhD, Sayed M

Age-Related Outcomes of the Ross Procedure Over 20 Years

Survival of Patients With or Without Symptoms Undergoing Potentially Curative Resections for Primary Lung Cancer Andrea R.G. Sheel, BS (Hons), MBChB,

Resection of Intraabdominal Tumors With Cavoatrial Extension Using Deep Hypothermic Circulatory Arrest Christopher Lau, MD, Padraic O’Malley, MD, Mario.

Performing Coronary Artery Bypass Grafting Off-Pump May Compromise Long-Term Survival in a Veteran Population Faisal G. Bakaeen, MD, Danny Chu, MD, Rosemary.

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

Survival After Lobectomy Versus Segmentectomy for Stage I Non-Small Cell Lung Cancer: A Population-Based Analysis Bryan A. Whitson, MD, PhD, Shawn S.

Use of Amiodarone After Major Lung Resection

Elizabeth A. David, MD, MAS, Stina W. Andersen, PhD, Laurel A

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Abel Gómez-Caro, MD, Pedro Arguis, MD The Annals of Thoracic Surgery

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Felix G. Fernandez, MD, Onkar Khullar, MD, Seth D

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Kathryn E. Engelhardt, MD, Malcolm M. DeCamp, MD, Anthony D

William M. Whited, MD, Paul Henley, BS, Erin M

Preoperative Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection Emilie Perrot, MD, Benoit Guibert, MD, Pierre Mulsant,

Pretransplant Panel Reactive Antibodies in Human Lung Transplantation: An Analysis of Over 10,000 Patients Ashish S. Shah, MD, Lois Nwakanma, MD, Christopher.

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD,

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Prognosis of Patients With Pathologic T0 N+ Esophageal Squamous Cell Carcinoma After Chemoradiotherapy and Surgical Resection: Results From a Nationwide.

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer? Anna Lee, MD, MPH, Andrew T.

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Trends in Patient Characteristics and Outcomes of Coronary Artery Bypass Grafting in the 2000 to 2012 Medicare Population Christian McNeely, MD, Stephen.

Prognostic Heterogeneity in Multilevel N2 Non-Small Cell Lung Cancer Patients: Importance of Lymphadenopathy and Occult Intrapulmonary Metastases Yukinori.

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

Modern Outcome and Risk Analysis of Surgically Resected Occult N2 Non-Small Cell Lung Cancer Hyun Jin Cho, MD, Sung Ryong Kim, MD, Hyeong Ryul Kim, MD,

Immediate and Long-Term Survival After Surgery for Lung Cancer in Heart Transplant Recipients Patrick Bagan, MD, Jalal Assouad, MD, Pascal Berna, MD,

Stefano Zoli, MD, Christian D

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Clinical Outcome After Pulmonary Resection for Lung Cancer Patients on Hemodialysis Toshiro Obuchi, MD, Wakako Hamanaka, MD, Yasuhiro Yoshida, MD, Jun.

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Mark I. Block, MD The Annals of Thoracic Surgery

The Impact of New Technology on Cardiothoracic Surgical Practice

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base

Induction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer Asad A. Shah, MD, Mark F. Berry, MD, Ching Tzao, MD,

Bryan M. Burt, MD, Santiago Ocejo, MD, Carlos M

Presentation transcript:

Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival Elizabeth A. David, MD, Robert J. Canter, MD, MAS, Yingjia Chen, MPH, David T. Cooke, MD, Rosemary D. Cress, DrPH The Annals of Thoracic Surgery Volume 102, Issue 4, Pages 1101-1109 (October 2016) DOI: 10.1016/j.athoracsur.2016.04.058 Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Distribution of treatment groups overall and by stage: (A) entire cohort; (B) stage IIIA; (C) stage IIIB; and (D) stage IV. (Chemo = chemotherapy; Rad = radiation; Surg = surgery.) The Annals of Thoracic Surgery 2016 102, 1101-1109DOI: (10.1016/j.athoracsur.2016.04.058) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Distribution of treatment groups by year: (A) stage IIIA; (B) stage IIIB; and (C) stage IV. **Denotes trend is significant (p < 0.05). (Blue line = chemotherapy only; red line = chemotherapy and radiation; green line = surgery, chemotherapy, and radiation; purple line = chemotherapy and surgery; teal line = surgery only; orange = surgery and radiation; light blue line = radiation only; pink line = no treatment; light green line = unknown.) The Annals of Thoracic Surgery 2016 102, 1101-1109DOI: (10.1016/j.athoracsur.2016.04.058) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Kaplan-Meier plots for overall survival: (A) entire cohort; (B) stage IIIA; (C) stage IIIB; and (D) stage IV. Hatchmarks indicate censored; log rank p less than 0.0001. (Chemo = chemotherapy; CR = chemotherapy and radiation; CRS = chemotherapy, radiation, surgery; CS = chemotherapy and surgery; NTx = no treatment; Rad = radiation; SURG = surgery.) The Annals of Thoracic Surgery 2016 102, 1101-1109DOI: (10.1016/j.athoracsur.2016.04.058) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions